Literature DB >> 10619350

Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells.

A Yuengsrigul1, T W Chin, E Nussbaum.   

Abstract

BACKGROUND: We have previously shown that children with mild asthma have a modest improvement in their pulmonary function tests after aerosolized furosemide. The mechanism of action is not known. The observation that furosemide possesses a similar profile of protection as sodium cromoglycate and nedocromil sodium suggests that furosemide may inhibit mediator production and release.
OBJECTIVE: We studied the in vitro effects of furosemide on cytokine release from normal human peripheral blood mononuclear cells (PBMC) induced by E. coli lipopolysaccharide (LPS).
METHODS: Peripheral blood mononuclear cells were isolated by density gradient centrifugation, stimulated with LPS and incubated at 37 degrees C with varying concentrations of furosemide, hydrocortisone, sodium cromoglycate, and nedocromil sodium for 24 hours. Supernatants were extracted and study for levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-8 (IL-8). Intracellular IL-6 and TNF-alpha concentrations were also measured by cell cytometry. Cell viability was examined using XTT cell proliferation test and-measuring the release of lactate dehydrogenase (LDH).
RESULTS: There was a significant reduction in levels of TNF-alpha and IL-6 at a furosemide concentration of 0.5 x 10(-2) M and a reduction in IL-8 levels at 10(-2) M. This inhibition was comparable to that found with equivalent molar concentrations of hydrocortisone. These findings were also confirmed with measurements of intracellular IL-6 and TNF-alpha by cell cytometry. High concentration of furosemide at 10(-2) M caused significant cellular cytotoxicity.
CONCLUSION: These data suggest that furosemide may exhibit an anti-inflammatory effect. Specifically, the addition of furosemide resulted in decreased production of cytokines. This effect may be due to an immunosuppressive activity on monocytes as well as a direct cytotoxic effect at high furosemide concentrations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619350     DOI: 10.1016/S1081-1206(10)62870-0

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  16 in total

Review 1.  Immunoparalysis and adverse outcomes from critical illness.

Authors:  W Joshua Frazier; Mark W Hall
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

2.  Topical furosemide versus oral steroid in preoperative management of nasal polyposis.

Authors:  Bozidar Kroflic; Andrej Coer; Tomislav Baudoin; Livije Kalogjera
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-10       Impact factor: 2.503

3.  Identification of a small molecule that facilitates the differentiation of human iPSCs/ESCs and mouse embryonic pancreatic explants into pancreatic endocrine cells.

Authors:  Yasushi Kondo; Taro Toyoda; Ryo Ito; Michinori Funato; Yoshiya Hosokawa; Satoshi Matsui; Tomomi Sudo; Masahiro Nakamura; Chihiro Okada; Xiaotong Zhuang; Akira Watanabe; Akira Ohta; Nobuya Inagaki; Kenji Osafune
Journal:  Diabetologia       Date:  2017-05-22       Impact factor: 10.122

Review 4.  Immune Modulation in Pediatric Sepsis.

Authors:  Mark W Hall
Journal:  J Pediatr Intensive Care       Date:  2019-01-02

Review 5.  Should Renal Inflammation Be Targeted While Treating Hypertension?

Authors:  Sarika Chaudhari; Grace S Pham; Calvin D Brooks; Viet Q Dinh; Cassandra M Young-Stubbs; Caroline G Shimoura; Keisa W Mathis
Journal:  Front Physiol       Date:  2022-06-13       Impact factor: 4.755

6.  An isomeric mixture of novel cerebrosides isolated from Impatiens pritzellii reduces lipopolysaccharide-induced release of IL-18 from human peripheral blood mononuclear cells.

Authors:  Xuefeng Zhou; Lan Tang; Yonghong Liu
Journal:  Lipids       Date:  2009-07-17       Impact factor: 1.880

7.  Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer.

Authors:  Kento Ishibuchi; Takamasa Iwakura; Mai Kaneko; Hirotaka Fukasawa; Ryuichi Furuya
Journal:  CEN Case Rep       Date:  2020-03-13

8.  The pharmacology of acute lung injury in sepsis.

Authors:  Brian Michael Varisco
Journal:  Adv Pharmacol Sci       Date:  2011-06-28

9.  Chronic rhinosinusitis and emerging treatment options.

Authors:  Patorn Piromchai; Pornthep Kasemsiri; Supawan Laohasiriwong; Sanguansak Thanaviratananich
Journal:  Int J Gen Med       Date:  2013-06-07

10.  Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis.

Authors:  Rachael L Disantostefano; Hao Li; David B Rubin; David A Stempel
Journal:  BMJ Open       Date:  2013-04-22       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.